Page 6 - HME Business, Jan/Feb 2019

Editor’s Note
The CBD Opportunity
CBD could help a lot of HME customers, but some things must happen before HMEs dive in.
Volume 26 Number 1 January/February 2019
It sounds trite to say, but many of your patients are in pain — real, honest-to-goodness pain. If they’re coming into your HME business for a knee brace, there’s a good chance they’re in pain. If they’re coming in for orthopedic footwear, they’re likely feeling some pain. If they’re coming in for a TENS unit, you know they’re in pain. In fact, for some providers, pain management represents a healthy percentage of their revenues.
So many of the conditions that HME clients must manage include some segment of pain. Frankly to not provide non-drug solutions for pain management seems like not only waste of a busi- ness opportunity, but almost a failure to live up to the patient relationship. People should have access to a spectrum of non-prescription pain manage- ment options, and HME providers are in an excel- lent position to offer those options.
Should CBD be part of that spectrum? I think it should be, but some things need to happen before it becomes a legitimate opportunity.
Let’s start with a definition. For those unfamiliar with CBD, it is one of two compounds called cannabinoids produced by the cannabis plant. The first cannabinoid most everyone has heard of is THC, the psychoactive component in recreational marijuana. CBD, also known as cannabidiol, is the cannabinoid often used in managing chronic pain, insomnia and anxiety.
CBD oils, lotions and pills are being sold online and at brick-and-mortar retail locations in states where it is legal to do so. CBD products are sold in varying dosages that might or might not contain very small percentages of THC, as well.
I can speak from personal experience on the efficacy of CBD: I bought some CBD oil over the Internet that completely managed chronic shoulder pain that has caused me many sleepless nights for more than a decade. My only other option were serious prescription medciations I did not want to take. It’s not surprising to me that many CBD advo- cates argue that, as a non-addictive painkiller, the drug could help address the opioid epidemic.
In terms of market size, CBD use has grown so widespread according to market researchers the Brightfield Group, the global CBD market could expand to $22 billion by 2022. Suffice it to say
EDITORIAL ADVISORY BOARD
Executive Editor Associate Editor
Art Director Production Coordinator
Director of Online Product Development
Group Publisher
Integrated Media Consultant
David Kopf
(949) 265-1561 Leila McNeill
Laurie Layman Charles Johnson
Marlin Mowatt Karen Cavallo
(760) 610-0800 Caroline Stover (323) 605-4398
that’s not a niche — it’s practically an economy unto itself. And it’s a market need that providers should consider serving given that many of their customers likely suffer some form of chronic pain.
There’s just one hitch: CBD still sits in a legal grey area. The Department of Justice and the Drug Enforcement Agency consider any part of cannabis — and that includes CBD — a narcotic, but they have not enforced any laws when it comes to what is called “industrial hemp” products that include less than 0.3 percent THC, which covers most CBD products. As a result, many farmers and others further down the CBD economy have been reticent to participate in the business — until now.
Enter the 2018 Farm Bill. As this issue was going to press, both the House and the Senate bill, which includes legislative language removing industrial hemp production from the Controlled Substances Act. As I type this the bill has gone to President Trump’s desk, where he is anticipated to sign it into law. This will further protect both hemp farmers and CBD sellers, which is a major reassurance.
That said, the Farm Bill is half the equation. CBD also needs real scientific research. Right now, me telling you that CBD completely handled my chronic shoulder pain is an unfounded claim. Well, that goes for all CBD claims. CBD needs to see some real research into its efficacy as well as its use. For instance, CBD can influence the liver’s cytochrome P450 enzyme system, which helps metabolize various compounds — including a whole host of drugs such as statins, steroids and antidepressants. Without research into these inter- actions, the medical community, providers and users are flying blind.
CBD needs FDA-approved research that cements its medical and pharmaceutical legitimacy and makes it a product that customers will trust. Providers offering CBD should push CBD manufac- turers to fund that research so they can confidently back it with their brands.
David Kopf Executive Editor HME Business
Steve Ackerman
President Spectrum Medical
Jeffrey S. Baird, Esq.
Chairman of the Health Care Group of Brown & Fortunato, P.C.
Cara Bachenheimer
Lobbyist/Government Af- fairs for Brown & Fortunato, P.C.
Rob Baumhover
Director of Retail Services for VGM Retail Services
Ty Bello, RCC
President and Founder Team@Work
Georgie Blackburn
Vice President, Government Relations and Legislative Affairs BLACKBURN’S
Rob Boyeye
Executive Vice President of HME Brightree LLC
Sandra Canally
President
The Compliance Team Inc.
George Coppola
Director of Marketing CAIRE Medical
John Letizia
President of Laurel Medical Supplies Inc.
Joe Lewarski
Vice President of Global Respiratory and Sleep Drive Devilbiss
Ron Resnick
President Blue Chip Medical Products Inc.
Tom Ryan
President and CEO AAHomecare
Wayne Slavitt
Founder and CEO Mobül: The Mobility Store
Wayne van Halem
President and Founder The van Halem Group LLC
INFRASTRUCTURE SOLUTIONS GROUP
President & Group Publisher Group Publisher Group Circulation Director Group Marketing Director Group Social Media Editor
Chief Executive Officer Chief Financial Officer Chief Technology Officer
Executive Vice President Executive Chairman
REACHING THE STAFF
Kevin O’Grady Karen Cavallo Irene Fincher Susan May Sydny Shephard
Rajeev Kapur Janet Brown Erik A. Lindgren
Michael J. Valenti Jeffrey S. Klein
Editors can be reached via e-mail, fax, telephone, or mail. A list of editors and contact information is at www.hme-business.com.
Email: email is routed to individuals’ desktops. Please use the following form: firstnameinitial,lastname@1105media.com. Do not include a middle name or middle initials.
Telephone: The switchboard is open weekdays 8:30 a.m. to 5:30 p.m. After 5:30 p.m. you will be directed to individual extensions.
Dallas Office: 14901 Quorum Drive, Suite 425, Dallas, TX 75254 (972) 687-6700; Fax: (972) 687-6799; www.1105media.com
Corporate Phone: (818) 814-5200; Fax: (818) 734-1522
6 HMEBusiness | January/February 2019 | hme-business.com
Management Solutions | Technology | Products